Filing summary
Filing identity: The request metadata identifies Lisata Therapeutics, Inc. and 2012 Q1, but the supplied filing is NeoStem, Inc.’s Form 10-Q for the quarter ended March 31, 2013. The figures below summarize the supplied filing; verify the intended issuer and period.
Business context and reporting period
NeoStem operated in one reporting segment, Cell Therapy, combining Progenitor Cell Therapy’s contract development and manufacturing services (CDMO) with proprietary cell-therapy development. Its main clinical program was AMR-001 for post-heart-attack patients. The comparison period is the three months ended March 31, 2012; China operations sold or exited in 2012 are presented as discontinued operations.
Key financial metrics
| Metric | Q1 2013 | Q1 2012 |
|---|---|---|
| Revenue | $2.52 million | $3.77 million |
| Gross profit and margin | $0.13 million; 5% | $0.82 million; 22% |
| Operating expenses | $8.96 million | $8.36 million |
| Operating loss | $8.83 million | $7.54 million |
| Loss from continuing operations | $8.86 million | $7.98 million |
| Net loss | $8.86 million | $9.21 million |
| Net loss per common share | $0.05 | $0.08 |
| Cash used in continuing operations | $7.14 million | $3.62 million |
| Cash and cash equivalents, quarter-end | $9.25 million | $7.00 million in continuing operations |
At March 31, 2013, working capital was approximately $3.4 million and stockholders’ equity was approximately $29.4 million. Total assets were $49.9 million and total liabilities were $20.9 million. Current liabilities were $9.23 million. Notes payable totaled approximately $0.3 million, mortgages payable $3.40 million, and acquisition-related contingent consideration $7.55 million. The mortgages were classified as current liabilities; the company reported prior covenant noncompliance and obtaining lender waivers for the specified measurement periods.
Material changes and management commentary
- Revenue fell 33%, mainly because third-party clinical-service contracts were completed and reimbursable activity declined. Processing and storage revenue rose 25% to about $0.8 million.
- Gross margin declined to 5% from 22%. Management attributed this primarily to lower third-party revenue, excess manufacturing capacity, and lower facility utilization.
- Research and development expense increased 62% to $3.16 million, principally with AMR-001 Phase 2 trial activity. Selling, general and administrative expense declined 10% to $5.80 million.
- Continuing-operations cash use increased to $7.14 million. Financing provided $2.71 million, including about $2.8 million gross proceeds from Aspire equity-line share sales and about $0.1 million from warrant exercises. Cash declined by $4.48 million during the quarter.
- The lower overall net loss versus Q1 2012 is not a like-for-like improvement in ongoing operations: the prior-year period included discontinued-operation losses, while the continuing-operations loss increased.
Outlook, risks, and unusual items
- Management expected to complete enrollment in the AMR-001 Phase 2 PreSERVE trial in 2013, with initial data expected six to eight months after the last patient is enrolled. As of April 30, 2013, 108 of the planned 160 patients had been enrolled; the FDA had authorized enrollment up to 180 if needed.
- The trial was estimated to cost about $16 million over its first two years and up to about $22 million over five years, including manufacturing costs; approximately $8.8 million had been incurred through March 31, 2013.
- Management said additional capital would be needed for cell-therapy development and business growth. It cited risks that financing may be unavailable or on unfavorable terms, potentially requiring delayed or discontinued programs or expansion.
- Subsequent to quarter-end, the company completed a public offering on May 3, 2013 of 23 million shares, including the fully exercised over-allotment, for $11.5 million gross proceeds before offering costs. This is a post-quarter event, not Q1 cash.
- Other notable items: the company used Level 3 valuation inputs for warrant derivatives and contingent consideration; it reported no material change in risk factors or legal proceedings from its 2012 Form 10-K and no material change in internal control over financial reporting.
Important facts for investors to verify
- Confirm that NeoStem’s Q1 2013 filing—not a Lisata Therapeutics filing or a 2012 period—is the intended source.
- Review cash runway and financing needs in light of the $7.14 million quarterly operating cash outflow, and confirm net proceeds from the May 2013 offering after fees.
- Track AMR-001 enrollment, trial spending, and timing of the expected data readout.
- Assess the sustainability of CDMO revenue and facility utilization given the revenue decline and gross-margin compression.
- Review mortgage covenant status and waivers, including the mortgages’ current classification and lender call provisions.